After three years of negotiations, the Spanish government and
Vertex Pharmaceuticals Inc. have agreed a payment-by-results reimbursement deal for the cystic fibrosis treatments, Orkambi (lumacaftor/ivacaftor) and Symkevi (tezacaftor/ivacaftor)....
Vertex Strikes Spanish Payment-For-Results CF Deal
Company & NHS England Hope To Announce New Deal Soon
Listen to this article
Vertex has struck a reimbursement deal in Spain for Orkambi and hopes that it will also make progress in England where a new proposal has been made by the company.
Learn what's happening at the US FDA. On the go.
More from Europe
• By
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
• By
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
More from Geography
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
• By
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.